Novo Nordisk And Gilead Expand NASH Alliance
Duo Exploring Combo Approaches To Treat Cirrhosis
Novo Nordisk and Gilead Sciences have expanded their clinical collaboration in non-alcoholic steatohepatitis following positive data from a proof-of-concept trial.
You may also be interested in...
The first clinical results from its mitochondrial derived peptide pipeline is good news for CohBar, but it needs investors or big pharma partners to help it progress.
Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.
Novo Nordisk’s semaglutide, a GLP-1 agonist marketed in an injected formulation as Ozempic, and an oral tablet form as Rybelsus, is a success story with the potential for an epic third act. First approved as a treatment for type 2 diabetes, semaglutide is under FDA review as a treatment for obesity, with additional clinical programs in NASH and Alzheimer’s disease.